Santen Pharmaceutical Co Ltd
OTC:SNPHF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Santen Pharmaceutical Co Ltd
OTC:SNPHF
|
JP |
|
P
|
Paninvest Tbk PT
XMUN:OA9
|
ID |
|
Mission Group PLC
F:M7K
|
UK |
|
Golden Rim Resources Ltd
F:ALM
|
AU |
|
T
|
Texas Capital Bancshares Inc
F:TCA
|
US |
|
G
|
Goldstorm Metals Corp
F:B2U
|
CA |
|
M
|
Melco International Development Ltd
OTC:MDEVY
|
HK |
|
B
|
Bechtle AG
SWB:BC8
|
DE |
|
H
|
Hang Lung Properties Ltd
XMUN:AOP
|
HK |
|
Career Design Center Co Ltd
OTC:CAEEF
|
JP |
|
Tungsten West PLC
LSE:TUN
|
UK |
|
B
|
Becket Invest PLC
LSE:TAB
|
UK |
|
Bitcoin Group SE
F:ADE
|
DE |
|
Tokyu Corp
F:01T
|
JP |
Wall St Price Targets
SNPHF Price Targets Summary
Santen Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for SNPHF is 16.39 USD with a low forecast of 13.38 USD and a high forecast of 20.51 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is SNPHF's stock price target?
Price Target
16.39
USD
According to Wall Street analysts, the average 1-year price target for SNPHF is 16.39 USD with a low forecast of 13.38 USD and a high forecast of 20.51 USD.
What is the Revenue forecast for Santen Pharmaceutical Co Ltd?
Projected CAGR
4%
Over the last 13 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 3 years is 4%.
What is the Gross Profit forecast for Santen Pharmaceutical Co Ltd?
Projected CAGR
3%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 2 years is 3%.
What is the Operating Income forecast for Santen Pharmaceutical Co Ltd?
Projected CAGR
29%
Over the last 13 years, the compound annual growth rate for Operating Income has been 5%. The projected CAGR for the next 1 year is 29%.
What is the Pre-Tax Income forecast for Santen Pharmaceutical Co Ltd?
Projected CAGR
6%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 5%. The projected CAGR for the next 2 years is 6%.
What is the Net Income forecast for Santen Pharmaceutical Co Ltd?
Projected CAGR
4%
Over the last 13 years, the compound annual growth rate for Net Income has been 6%. The projected CAGR for the next 2 years is 4%.
